FC06.08

Impact of Psoriatic Disease on Mental Health: Results from the Global Psoriasis and Beyond study

April Armstrong,[1] Barbra Bohannan,[2] Sicily Mburu,[3] Laura C Coates,[4] Alexis Ogdie,[5]
Elena Kornyeyeva,[6] Susan Frade,[6] Silvia Fernandez Barrio,[7] Matthias Augustin[8]

[1] *Department of Dermatology, University of Southern California, Los Angeles, CA, United States*

[2] *Psoriasisförbundet, Stockholm, Sweden*

[3] *International Federation of Psoriasis Associations, Stockholm, Sweden*

[4] *Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom*

[5] *Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States*

[6] *Novartis Pharma AG, Basel, Switzerland*

[7] *Asociación Para El Enfermo De Psoriasis, Buenos Aires, Argentina*

[8] *University Medical Center Hamburg-Eppendorf, Hamburg, Germany*

PSORIASIS AND BEYOND
THE GLOBAL PSORIATIC DISEASE SURVEY

Disclosures

- **April Armstrong** serves as research investigator and/or scientific advisor to AbbVie, BI, BMS, EPI, Incyte, Leo Pharma, UCB, Janssen, Eli Lilly, Novartis, Ortho Dermatologics, Sun, Dermavant, Dermira, Sanofi, Regeneron, and Pfizer
- **Sicily Mburu, Barbra Bohannan** and **Silvia Fernandez Barrio** have no conflicts of interests
- **Laura C Coates** has received grants/research support from AbbVie, Amgen, Celgene, Eli Lilly, Janssen, Novartis, Pfizer and UCB; worked as a paid consultant for AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Gilead, Galapagos, Janssen, Moonlake, Novartis, Pfizer and UCB; and has been paid as a speaker for AbbVie, Amgen, Biogen, Celgene, Eli Lilly, Galapagos, Gilead, GSK, Janssen, Medac, Novartis, Pfizer and UCB
- **Alexis Ogdie** has served as a consultant for Abbvie, Amgen, BMS, Celgene, CorEvitas, Gilead, GSK, Janssen, Eli Lilly, Novartis, Pfizer, UCB and had received grant funding to the University of Pennsylvania from Abbvie, Novartis and Pfizer and to Forward databank from Amgen
- **Elena Kornyeyeva and Susan Frade** are full time employees at Novartis Pharma AG, Basel, Switzerland
- **Matthias Augustin** has served as consultant or has been a paid speaker for clinical trials sponsored by companies that manufacture drugs used for the treatment of psoriasis, including Abbvie, Almirall, Amgen, Biogen, Boehringer Ingelheim, Celgene, Centocor, Eli Lilly, GSK, Janssen-Cilag, Leo Pharma, Medac, Merck, MSD, Novartis, Pfizer, UCB, and Xenoport

Acknowledgements

All authors participated in the development of the poster for presentation. The authors thank Nivedita Jangale (Novartis Healthcare Pvt. Ltd., India) and Trudy McGarry (Novartis, Dublin, Ireland) for editorial and medical writing support, which was funded by Novartis Pharma AG, Basel, Switzerland in accordance with the Good Publication Practice (GPP3) guidelines (http://www.ismpp.org/gpp3).

This investigation was sponsored by Novartis Pharma AG, Basel, Switzerland.

Presentation at the 31st European Academy of Dermatology and Venereology (EADV) Congress, Milan, Italy, September 10, 2022, 15:25 - 15:35 CET

Psoriasis and Beyond: The Global Psoriasis Disease Study

AIM: To assess patients’ understanding of the systemic nature of psoriatic disease (PsD), related manifestations and comorbidities, and the impact of PsD on QoL and relationship with HCPs

COLLABORATION: IFPA, Novartis, Ipsos SA, committee of patient advocates, and dermatology and rheumatology medical experts

PRIMARY RESULT: Patients with PsD do not fully understand the systemic nature of their disease and may require additional education

20 countries*

4978 participants

▶ **12 Nov 2020**

■ **13 June 2021**

In this presentation, we report the impact of psoriatic disease (PsD) on mental health

---

*Austria, Australia, Belgium, Chile, Canada, Denmark, France, Germany, India, Ireland, Italy, Japan, Norway, Romania, Russia, Slovenia, South Korea, Taiwan, UK, USA

HCPs, healthcare professionals; IFPA, International Federation of Psoriasis Associations; Ipsos SA, Institut de Publique Sondage d'Opinion Secteur; PsD, psoriatic disease; QoL, quality of life

Armstrong A, et al. *Fall Clinical Dermatology Conference*, Las Vegas, United States, October 21–24, 2021.

Study Participants



Total
N=4978

49%
mean age 42.5 years

51%
mean age 44.0 years

Diagnosis at the time of recruitment



38%

of the total patients with plaque PsO (n=3490) screened positive for PsA using the PEST tool*

Current plaque PsO severity#



Many of the patient with mild plaque PsO presented disease located in hard-to-treat areas (mainly scalp (53%) and face (26%)

*The PEST was developed to assist in identifying PsA at an early stage. #The results in this presentation are based on 'current plaque PsO severity'.
PEST, Psoriasis Epidemiology Screening Tool; PsA, psoriatic arthritis; PsO, psoriasis
Armstrong A, et al. *Fall Clinical Dermatology Conference*, Las Vegas, United States, October 21–24, 2021.

Base: all patients (n=4978)

Comorbidities related to mental health



Anxiety or depression was frequent, irrespective of disease severity

Base: all patients (n=4978)

PEST, Psoriasis Epidemiology Screening Tool; PsO, psoriasis

Impact on QoL



Extremely large effect: DLQI 21–30
Very large effect: DLQI 11–20
Moderate effect: DLQI 6–10
Small effect: DLQI 2–5
No effect: DLQI 0–1

Psychological comorbidities had a substantial effect on patient’s QoL

Base: all patients (n=4978)

DLQI, Dermatology Life Quality Index; QoL, quality of life

Emotional impact of PsD



In total, 36% of all patients reported that PsD greatly impacted their overall emotional well-being

*Question: How does living with plaque PsO/ PsO and PsA make you feel? Top 8 options of the question selected.
PsA, psoriatic arthritis; PsD, psoriatic disease; PsO, psoriasis

Base: all patients (n=4978)

Stigma and discrimination experienced due to PsD



In total, 82% of patients reported experiencing both stigma and discrimination

*e.g., Refusal to provide me a treatment at a beauty clinic/cosmetic studio, people refusing to serve me in shops, being asked to leave a form of public transport.
Question: Have you ever experienced any of the following due to your plaque PsO/ PsO and PsA? Top 9 options of the question selected.
PsD, psoriatic disease; PsO, psoriasis

Base: all patients (n=4978)

Trust in health care professionals



In total, 35% of total patients with PsD did not feel listened to by their HCPs*

*Question: Please look at the statements, how much do you agree with them. (Scale from 1 to 5 [1=Completely disagree, 3=Neutral, 5= Completely agree])
HCPs, health care professionals PsD, psoriatic disease

Base: all patients (n=4978)

Conclusions

PsD has a negative impact on mental health and QoL

Increase the awareness of PsD and the understanding of its emotional impact

Consider the emotional/social impact of PsD when assessing the disease

Adopt a personalized, psycho-dermatological treatment approach

HCP, healthcare professional; PsD, psoriatic disease; QoL, quality of life

Thank you

Q&A